EyePoint Pharmaceuticals announced that it has commenced an underwritten public offering of $175M of shares of its common stock. All of the shares are being offered by EyePoint. EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901 for wet age related macular degeneration through the initiation of and reporting of topline data from two pivotal Phase 3 clinical trials, as well as support its earlier stage pipeline development initiatives, and for general corporate purposes. J.P. Morgan, TD Cowen and Guggenheim Securities are acting as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EYPT:
- EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
- EyePoint reports inducement grants under Nasdaq listing rule
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint management to meet with Cantor Fitzgerald
- EyePoint price target lowered to $25 from $27 at H.C. Wainwright